Regeneron Pharmaceuticals Inc (REGN)
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (86%) **Content type:** Clinical